CAPR

6.34

9.04% -0.63

Handel nachbörslich: 6.30 -0.04 -0.63%

Capricor Therapeutics Inc (CAPR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CAPR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$6.97

Offen:

$6.99

24-Stunden-Volumen:

3.63M

Relative Volume:

2.24

Marktkapitalisierung:

$541.73M

Einnahmen:

$27.10M

Nettoeinkommen (Verlust:

$-24.31M

KGV:

-7.6386

EPS:

-0.83

Netto-Cashflow:

$-33.33M

1W Leistung:

-46.54%

1M Leistung:

-32.55%

6M Leistung:

-67.82%

1J Leistung:

+16.97%

1-Tages-Spanne:

$6.27

$7.10

1-Wochen-Bereich:

$6.27

$11.32

52-Wochen-Spanne:

$3.52

$23.40

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Firmenname

Capricor Therapeutics Inc

Sektor

Healthcare (1153)

Branche

Biotechnology (676)

Telefon

(310) 358-3200

Adresse

8840 WILSHIRE BLVD, BEVERLY HILLS, CA

Mitarbeiter

160

Twitter

@Capricor

Nächster Verdiensttermin

2025-03-19

Neueste SEC-Einreichungen

CAPR's Discussions on Twitter

Vergleichen Sie CAPR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CAPR Capricor Therapeutics Inc	6.34	541.73M	27.10M	-24.31M	-33.33M	-0.83
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-21	Eingeleitet	Piper Sandler	Overweight
2024-05-17	Eingeleitet	Oppenheimer	Outperform
2024-01-05	Eingeleitet	Cantor Fitzgerald	Overweight
2022-10-26	Eingeleitet	Ladenburg Thalmann	Buy
2018-12-26	Herabstufung	Maxim Group	Buy → Hold
2018-01-26	Bestätigt	H.C. Wainwright	Buy
2017-09-15	Bestätigt	H.C. Wainwright	Buy
2017-02-13	Fortgesetzt	Rodman & Renshaw	Buy
2016-07-06	Fortgesetzt	H.C. Wainwright	Buy
2016-06-15	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten

May 09, 2025

Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud InvestigationCAPR - ACCESS Newswire

May 09, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph

May 09, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.

May 09, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - GlobeNewswire Inc.

May 09, 2025

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet - simplywall.st

May 09, 2025

May 08, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire

May 08, 2025

May 07, 2025

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

May 07, 2025

How the (CAPR) price action is used to our Advantage - news.stocktradersdaily.com

May 07, 2025

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga

May 07, 2025

May 06, 2025

Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - MSN

May 06, 2025

Capricor Therapeutics to Present First Quarter 2025 Financial Re - GuruFocus

May 06, 2025

Capricor Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on May 13 - Nasdaq

May 06, 2025

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewswire

May 06, 2025

May 05, 2025

Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duchenne Treatment | CAPR Stock News - GuruFocus

May 05, 2025

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy - Endpoints News

May 05, 2025

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters

May 05, 2025

Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop - GuruFocus

May 05, 2025

Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com

May 05, 2025

Capricor Share Slide 12% as FDA Calls Advisory Panel for Duchenne Cardiomyopathy Therapy - paginasiete.bo

May 05, 2025

Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic - Asianet Newsable

May 05, 2025

Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView

May 05, 2025

Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus

May 05, 2025

CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus

May 05, 2025

Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire

May 05, 2025

FDA Fast-Tracks Revolutionary DMD Heart Treatment as Capricor Clears Major Regulatory Hurdle - Stock Titan

May 05, 2025

Barclays PLC Has $1.24 Million Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

May 05, 2025

May 04, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co. - Defense World

May 04, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus Target Price from Analysts - Defense World

May 04, 2025

May 03, 2025

Wells Fargo & Company MN Sells 4,641 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

May 03, 2025

May 02, 2025

Capricor Therapeutics Inc (NASDAQ: CAPR) Stock Gained 34.46% Over A Month – Any Room To Run? - Marketing Sentinel

May 02, 2025

May 01, 2025